Keystone Bio is developing a first‐of‐kind bio‐therapeutic, and a new suite of diagnostics, therapeutics, and monoclonal antibodies in the multi‐billion‐dollar arena of Alzheimer’s and Heart Disease.

 

Keystone Bio is initiating Phase I/II clinical trials for its proprietary first-of-kind bio-therapeutic-drug for heart disease targeting volatile coronary artery plaque and post-event myocardium vulnerability.

Brain CEREBRUM anatomy - cross section

“We have known for some time that what is good for your heart is good for your head.”

Clare Watson
Research Committee Manager
Alzheimer’s Society UK 

KEYSTONE BIO PROPRIETARY SOLUTIONS

Dna double helix molecules and chromosomes

Bio-Therapeutics & Diagnostic

Bio-therapeutic and next-generation point-of-care diagnostic suite for Alzheimer’s disease and multiple cardiovascular diseases.

Picture3

Licensing Agreements

Licensing Agreements utilizing Keystone Bio IP, co-developing therapeutics  (monoclonal antibodies) for Alzheimer’s disease & multiple cardiovascular diseases. Proprietary management systems (OMS) for hospitals, assisted living, medical, and dental facilities.

INCREDIBLE NUMBERS

Number of people with Alzheimer's disease in the United States alone.

Number of Americans that die from cardiovascular disease each year.

“Never before has there been the opportunity to make such a huge impact on the lives of so many.”